Program
VXA-G2.4-NS
Its studies are mostly in Caliciviridae Infections, led by Vaxart.
Furthest: phase 1, since Mar 28, 20193 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vaxart | 30 open or running | phase 1since Mar 28, 2019 | Mar 28, 2019 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 28, 2019First study: phase 1 study in Caliciviridae InfectionsFirst studyNCT03897309 · 86 enrolled · United States
- Apr 17, 2025Phase 1 study in Caliciviridae InfectionsNCT06944717 · 60 enrolled · United States
- Nov 19, 2025Phase 1 study in Caliciviridae InfectionsNCT07254728 · 76 enrolled · South Africa
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07254728Caliciviridae Infections · South Africa | 1 | Completed | Dec 13, 2024 | 76 |
| NCT06944717Caliciviridae Infections · United States | 1 | Completed | Apr 14, 2026 | 60 |
| NCT03897309Caliciviridae Infections · United States | 1 | Completed | Jan 15, 2021 | 86 |
How it is read
Names in the registry
- “VXA-G2.4-NS”, 3 entries
Conditions, from the studies’ own filings
- Caliciviridae Infections, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.